These are glimpses into the work we do, the things we care about, and the milestones we’re working towards.

Supporting Research to Help People with Neglected Tropical Diseases

A new Harvard case study examines why AbbVie works on Neglected Tropical Diseases (NTDs) in alliance with key nonprofits.

 

Pediatric Outreach Strong in Romania and Malawi

AbbVie and Baylor College of Medicine team up again to renovate and expand children’s health facilities in Romania and Africa.

 

Employee Outreach Making a Difference in Communities

AbbVie employees make a global effort to improve underserved communities during Week of Possibilities.  
 

AbbVie Recognized as One of the Best Workplaces in Europe by Great Place to Work®

Great Place to Work® recognized AbbVie for creating a work environment that fosters innovation, personal development and collaboration.
 

World Health Assembly Commits to Eliminate Viral Hepatitis Threat by 2030

The World Health Assembly adopted the World Health Organization (WHO) viral hepatitis strategy to reduce mortality rates, increase screening and treatment for hepatitis B and C.

Ten Facts You Should Know About the Most Common Adult Leukemia

This week, AbbVie joins the oncology community at the American Society of Clinical Oncology (ASCO) annual meeting to take a closer look at chronic lymphocytic leukemia (CLL). 

World Health Organization (WHO) Publishes Global Report on Psoriasis

The report aims to raise awareness of psoriasis and fight negative perceptions of people living with disease. The complexity of the disease requires a more holistic “whole person” approach to care.
 

Our Foundational Neuroscience Center Opens in Cambridge, Massachusetts

A 43,000-square-foot research center in the Cambridge, Massachusetts, biotech corridor will be devoted to neurodegenerative diseases such as Alzheimer’s.
 

Expanding Our Cystic Fibrosis Collaboration with Galapagos

The cystic fibrosis (CF) combination therapy we are developing with Galapagos is on track. Following successful completion of Phase 2 development, AbbVie will be responsible for Phase 3.
 

First Quarter 2016 Financial Results

We believe 2016 is off to an exceptional start, with double-digit sales and adjusted earnings growth in the first quarter. Read the full news release.